QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Provides Update on Advancements of Proprietary Biosynthesis Technology

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning provided an update to its investors on the significant advancements in the development of its proprietary technology for the microbial biosynthesis of cannabinoids. InMed has successfully demonstrated that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms. These molecules can be further functionalized to produce any of the 90+ cannabinoids that occur naturally in the cannabis plant. “Successful scale-up and commercialization of the biosynthesis process for cannabinoid production is a top priority for InMed,” Eric A. Adams, president and CEO of InMed, stated in the news release. “We are dedicating substantial resources to this project and have retained key individuals as we transition into the advanced pilot and to the commercialization phases of development. The breadth and depth of our patents, currently either submitted or being prepared for submission, will provide significant protection to the entire process.”

To view the full press release, visit http://dtn.fm/Wc4bP

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.